Antiepileptic drug treatment: New drugs and new strategies

CONTINUUM Lifelong Learning in Neurology

Volumn 19, Issue 3, 2013, Pages 643-655

  French, Jacqueline A ^a   Gazzola, Deana M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BROMINE DERIVATIVE; CARBAMAZEPINE; ESLICARBAZEPINE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PERAMPANEL; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; RETIGABINE; RUFINAMIDE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ABNORMAL THINKING; ABSENCE; ACNE; ACUTE HEMORRHAGIC PANCREATITIS; ADD ON THERAPY; AGGRESSION; ALLERGIC REACTION; ANGER; ANOREXIA; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; APLASTIC ANEMIA; ASTHENIA; ATAXIA; ATONIC SEIZURE; BEDTIME DOSAGE; BEHAVIOR CHANGE; BLOOD TOXICITY; CLOSED ANGLE GLAUCOMA; COGNITION; COMORBIDITY; CONFUSION; COORDINATION DISORDER; DEEP VEIN THROMBOSIS; DELIRIUM; DEPRESSION; DIPLOPIA; DIZZINESS; DROWSINESS; DRUG CHOICE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; EPILEPTIC STATE; FALLING; FATIGUE; FOCAL EPILEPSY; FULMINANT HEPATIC FAILURE; GENERALIZED EPILEPSY; GINGIVA HYPERPLASIA; GRANULOMATOUS SKIN DISEASE; HAIR LOSS; HEADACHE; HIRSUTISM; HOSTILITY; HUMAN; HYPERACTIVITY; HYPERAMMONEMIA; HYPONATREMIA; INFANTILE SPASM; INSOMNIA; IRRITABILITY; LANGUAGE DISABILITY; LENNOX GASTAUT SYNDROME; LETHARGY; LEUKOPENIA; LIVER FAILURE; LIVER TOXICITY; LOW DRUG DOSE; LUPUS VULGARIS; MENTAL CONCENTRATION; METABOLIC ACIDOSIS; MOOD CHANGE; MORNING DOSAGE; MYOCLONUS EPILEPSY; MYOCLONUS SEIZURE; NAUSEA; NEPHROLITHIASIS; NERVOUSNESS; NEUROTOXICITY; NYSTAGMUS; OLIGOHYDRAMNIOS; PARESTHESIA; PORPHYRIA CUTANEA TARDA; PSYCHOSIS; RASH; RESTLESSNESS; REVIEW; SEIZURE; SIDE EFFECT; SKIN DEFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SUICIDAL IDEATION; THREAT; THROMBOCYTOPENIA; TONIC CLONIC SEIZURE; TOXIC EPIDERMAL NECROLYSIS; TREMOR; URINE RETENTION; VERTIGO; VISUAL FIELD DEFECT; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; AGED; ANTICONVULSANTS; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84880173902     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000431380.21685.75     Document Type: Review

References (27)

1. French JA, Gazzola DM. New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety? Therap Adv Drug Saf 2011;2(4):141-158.
2. Beydoun A. Monotherapy trials of new antiepileptic drugs. Epilepsia 1997;38(suppl 9): S21-S31.
3. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62(8):1252-1260. (Pubitemid 38526035)
4. Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007;68(6): 402-408. (Pubitemid 46208740)
5. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007;369(9566):1000-1015. (Pubitemid 46436124)
6. Baulac M, Brodie MJ, Patten A, et al. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol 2012;11(7):579-588.
7. Chaves J, Sander JW. Seizure aggravation in idiopathic generalized epilepsies. Epilepsia 2005;46(suppl 9):133-139. (Pubitemid 44921991)
8. Pesaturo KA, Spooner LM, Belliveau P. Vigabatrin for infantile spasms. Pharmacotherapy 2011;31(3):298-311.
9. Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010;362(2):790-799.
10. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007;369(9566): 1016-1026. (Pubitemid 46436125)
11. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992;327(11): 765-771.
12. Brodie MJ, Barry SJ, Bamagous GA, et al. Patterns of treatment response in newly diagnosed epilepsy. Neurology 2012;78(20):1548-1554.
13. Kalviainen R, Aikia M, Saukkonen AM, et al. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. Arch Neurol 1995;52(10):989-996.
14. Kwan P, Brodie MJ, Kalviainen R, et al. Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial. Lancet Neurol 2011;10(10):881-890.
15. Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res 1997;26(3):423-432. (Pubitemid 27146300)
16. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003;2(6): 347-356. (Pubitemid 38352562)
17. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003b;2(8):473-481. (Pubitemid 36876104)
18. Schmitz B. Effects of antiepileptic drugs on mood and behavior. Epilepsia 2006; 47(suppl 2):28-33. (Pubitemid 44684616)
19. Pennell PB. 2005 AES annual course: evidence used to treat women with epilepsy. Epilepsia 2006;47(suppl 1): 46-53. (Pubitemid 44527135)
20. Pack AM. Treatment of epilepsy to optimize bone health. Curr Treat Options Neurol 2011;13(4):346-354.
21. Harden CL, Meador KJ, Pennell PB, et al. Management issues for women with epilepsyVFocus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009;50(5):1237-1246.
22. Holmes LB, Wyszynski DF, Baldwin EJ, et al. Increased risk for non-syndromic cleft palate among infants exposed to lamotrigine during pregnancy(abstract). Birth Defects Rese Part A. Clin Mol Teratol 2006;76(5):318.
23. Herná ndez-Díaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012;78(21): 1692-1699.
24. Martinez-Frias ML. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2009;72(23):2054-2055; author reply 2055.
25. Sabers A. Algorithm for lamotrigine dose adjustment before, during, and after pregnancy. Acta Neurol Scand 2012;126(1): e1-e4.
26. Leppik IE. Epilepsy in the elderly. Epilepsia 2006;47(suppl 1):65-70. (Pubitemid 44527138)
27. Leppik IE. Treatment of epilepsy in the elderly. Curr Treat Options Neurol 2008;10(4):239-245.